Digital Microbes Used To Simulate Treatment Responses
Complete the form below to unlock access to ALL audio articles.
Researchers at University of Galway associated with APC Microbiome Ireland, a world-leading SFI Research Centre, have created a resource of over 7,000 digital microbes – enabling computer simulations of how drug treatments work and how patients may respond. The resource is a milestone in scientific understanding of human response to medical treatment as it offers the opportunity for computer simulations and predictions of differences in metabolism between individuals, including for diseases such as inflammatory bowel, Parkinson’s and colorectal cancer.
The database - called AGORA2 - builds on the expertise developed in the creation of first resource of digital microbes known as AGORA1. AGORA2 encompasses 7,203 digital microbes, created based on experimental knowledge from scientific publications, with a particular focus on drug metabolism.
The resource has been built by a team of scientists at University of Galway’s Molecular Systems Physiology group, led by APC Microbiome Ireland principal investigator Professor Ines Thiele.
The team’s research aims to advance precision medicine by using computational modelling.
Professor Thiele explained: “AGORA2 is a milestone towards personalised, predictive computer simulations enabling the analysis of person-microbiome-drug interactions for precision medicine applications.
“Humans are hosting a myriad of microbes. Just like us, these microbes eat and interact with their environment. Considering that we are all unique, each of us hosting an individual microbiome our metabolism is also expected to vary between individuals.
“The insight provided by the database of digital microbes presents a healthcare opportunity to harness individual differences in metabolism to provide personalised, improved treatments in ‘precision medicine’, compared to a currently more general ‘one-size-fits-all’ approach.
“Besides our food, our individual microbiomes also metabolise the medicines we take. The same drug may therefore manifest diverse effects in disparate people because of the differences in metabolism performed by the different microbiomes.”
Using the digital microbe resource AGORA2, computer simulations have shown that drug metabolism varies significantly between individuals, as driven by their own microbiome.
Uniquely, the AGORA2-based computer simulations enabled the identification of microbes and metabolic processes for individual drugs correlated with observations in a clinical setting.
The research was published today in Nature Biotechnology.
The team at University of Galway demonstrated that AGORA2 enables personalised, strain-resolved modelling by predicting the drug conversion potential of the gut microbiomes from 616 colorectal cancer patients and controls, which greatly varied between individuals and correlated with age, sex, body mass index and disease stages. This means that the team can create digital representations and predictions specific to the divergent microbes.
Professor Thiele added: “Knowledge of our individual microbiomes and their drug metabolising capabilities represents a precision medicine opportunity to tailor drug treatments to an individual to maximise health benefit while minimising side effects.
“By using AGORA2 in computer simulations our team have showed that the resulting metabolic predictions enabled superior performance compared to what was possible to date.”
Professor Paul Ross, Director of APC Microbiome Ireland, said: “This research is a perfect illustration of the power of computational approaches to enhance our understanding of the role of microbes in health and disease – significantly this digital platform will be a fantastic resource that could lead to the development of novel personalised therapeutic approaches which take the microbiome into account.”
Reference: Heinken A, Hertel J, Acharya G, et al. Genome-scale metabolic reconstruction of 7,302 human microorganisms for personalized medicine. Nat Biotechnol. 2023:1-12. doi: 10.1038/s41587-022-01628-0
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.